

January 11, 2018

Company name: RIBOMIC Inc.
Stock code: 4591
Listing: TSE, Mothers Market
URL: <http://www.ribomic.com/en/>

Pre-IND meeting with the U.S. FDA for clinical trials of age-related macular degeneration with RBM-0007 is scheduled for January 26.

We are planning a clinical trial in the United States for age-related macular degeneration with in-house developed agent, RBM-007 (anti FGF2 aptamer). We are pleased to inform you that this pre-IND meeting will be held on January 26 with the U.S. FDA (Food and Drug Administration), which is the regulatory authority for Investigational New Drug Application.

The pre-IND Briefing Package (IND Application draft for this meeting) was completed and submitted to the FDA by the end of last year. The purpose of this meeting is to prepare more appropriate IND Application including the development program into which FDA's recommendations and answers responding to our questions will be integrated.

The meeting will be attended by four members from the Ribomic Head Office, including the President and CEO of RIBOMIC, and President and CEO of Ribomic USA Inc. In addition, three specialist advisors will attend the meeting, including Dr. Robert B. Bhisitkul, a scientific advisor at the University of California, San Francisco Medical Center, Department of Ophthalmology.

We hope to obtain a fair understanding and evaluation of the RBM-007 clinical trial plan through discussions with a number of FDA's specialists familiar with each therapeutic area to file IND Application.

[About RBM-007]

RBM-007 is an aptamer that specifically inhibits fibroblast growth factor-2 (Fibroblast Growth Factor 2, FGF2).

RBM-007 exhibits a dual novel effect, not only to inhibit angiogenesis targeted by anti VEGF drugs, which are currently used in the treatment of AMD, but also to inhibit fibrosis (scarring in the retina), which cannot be completely prevented by anti VEGF drugs.

RBM-0007 with these two different effects is expected to be an innovative therapeutic agent

for AMD.

Profile of RIBOMIC

RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is a type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug development platform, can be used for the development of many types of aptamer drugs. RIBOMIC is dedicated to the discovery of drugs that target the broad field of unmet medical needs, which encompasses pain, eye disorders, fibrosis and many other problems.

【Inquiries:Corporate Planning Department +81-3-3440-3745】